Galmed Pharma (GLMD) Tops Q3 EPS by 6c

Galmed Pharma (NASDAQ: GLMD) reported Q3 EPS of ($0.23), $0.06 better than the analyst estimate of ($0.29).

For earnings history and earnings-related data on Galmed Pharma (GLMD) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• The Lovesac Company (LOVE) Tops Q1 EPS by 29c
• UBS Reiterates Neutral Rating on Clorox (CLX) as External Challenges Persist